EZH2 and prostate carcinoma: There are also many potent and more bioavailable EZH2 catalytic inhibitors currently undergoing phase 1/2/3 clinical trials, alone or in combination with other drugs, for the treatment of several solid tumors, mainly lymphoma, prostate cancer, and small cell lung cancer (Table 3).